Gan&Lee Pharmaceuticals. (SHA: 603087) has announced that the company has received a drug registration approval (approval number: BT004008102026) issued by El Salvador's General Directorate of Health Regulation for its insulin glargine injection (prefilled pen).
Insulin glargine is a basal long-acting insulin that is administered via subcutaneous injection once daily, with a glucose-lowering effect lasting for 24 hours.
It is characterized by a long duration of action, stable blood drug concentration without peaks, and steady glucose control.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments